{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T05:06:41Z","timestamp":1779772001332,"version":"3.53.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204207"],"award-info":[{"award-number":["82204207"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-026"],"award-info":[{"award-number":["2021-I2M-1-026"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bmc.2025.118338","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:12:13Z","timestamp":1754431933000},"page":"118338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Rational design, synthesis, and evaluating primary biological activities of novel HIV-1 protease inhibitors containing heteraryl acetamides as the P2 ligands"],"prefix":"10.1016","volume":"129","author":[{"given":"Sihan","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bmc.2025.118338_bb0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cid\/ciaa1240","article-title":"Burden of hypertension, diabetes, cardiovascular disease, and lung disease among women living with human immunodeficiency virus (HIV) in the United States","volume":"73","author":"Birabaharan","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.bmc.2025.118338_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/nu14153076","article-title":"The potential of Spirulina platensis to ameliorate the adverse effects of highly active antiretroviral therapy (HAART)","volume":"14","author":"Sibiya","year":"2022","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.bmc.2025.118338_bb0015","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/ijc.32730","article-title":"HIV-1, HAART and cancer: a complex relationship","volume":"146","author":"Shmakova","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bmc.2025.118338_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114554","article-title":"HIV nucleoside reverse transcriptase inhibitors","volume":"240","author":"Amblard","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"12","key":"10.1016\/j.bmc.2025.118338_bb0025","doi-asserted-by":"crossref","first-page":"e1699","DOI":"10.1016\/S2214-109X(22)00462-4","article-title":"The virological consequences of low-level viraemia","volume":"10","author":"Olakunde","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.bmc.2025.118338_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115501","article-title":"HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues","volume":"257","author":"Lockbaum","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"11","key":"10.1016\/j.bmc.2025.118338_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22116070","article-title":"Off-target-based Design of Selective HIV-1 PROTEASE inhibitors","volume":"22","author":"La Monica","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"suppl 18","key":"10.1016\/j.bmc.2025.118338_bb0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s12859-020-03825-7","article-title":"Evolution of drug resistance in HIV protease","volume":"21","author":"Shah","year":"2020","journal-title":"BMC Bioinf"},{"issue":"7","key":"10.1016\/j.bmc.2025.118338_bb0045","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/QAD.0000000000002516","article-title":"HIV protease inhibitor ritonavir induces renal fibrosis and dysfunction: role of platelet-derived TGF-\u03b21 and intervention via antioxidant pathways","volume":"34","author":"Laurence","year":"2020","journal-title":"Aids"},{"issue":"2","key":"10.1016\/j.bmc.2025.118338_bb0050","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0149-2918(97)80110-5","article-title":"Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus","volume":"19","author":"Lewis","year":"1997","journal-title":"Clin Ther"},{"key":"10.1016\/j.bmc.2025.118338_bb0055","unstructured":"Saquinavir (Roche protease inhibitor) at higher doses. AIDS Treat News, 1995(no 231): p. 5."},{"key":"10.1016\/j.bmc.2025.118338_bb0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.coviro.2021.09.009","article-title":"Drug resistance mutations in HIV: new bioinformatics approaches and challenges","volume":"51","author":"Blassel","year":"2021","journal-title":"Curr Opin Virol"},{"issue":"6","key":"10.1016\/j.bmc.2025.118338_bb0065","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.immuni.2022.03.004","article-title":"Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones","volume":"55","author":"Collora","year":"2022","journal-title":"Immunity"},{"issue":"7822","key":"10.1016\/j.bmc.2025.118338_bb0070","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bmc.2025.118338_bb0075","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00018-022-04421-z","article-title":"HIV cure strategies: which ones are appropriate for Africa?","volume":"79","author":"Abana","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10.1016\/j.bmc.2025.118338_bb0080","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3855\/jidc.12519","article-title":"Cumulative effects of hypertriglyceridemia in HIV-infected patients switching from NNRTIs to PI-based antiretroviral therapy","volume":"16","author":"Zhang","year":"2022","journal-title":"J Infect Dev Ctries"},{"issue":"2","key":"10.1016\/j.bmc.2025.118338_bb0085","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01715-21","article-title":"Fluorine modifications contribute to potent antiviral activity against highly drug-resistant HIV-1 and Favorable blood-brain barrier penetration property of novel central nervous system-targeting HIV-1 protease inhibitors in vitro","volume":"66","author":"Amano","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.bmc.2025.118338_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/v12111275","article-title":"Darunavir-resistant HIV-1 protease constructs uphold a conformational selection hypothesis for drug resistance","volume":"12","author":"Liu","year":"2020","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.bmc.2025.118338_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/v16010010","article-title":"Impact of protease inhibitor-based highly active antiretroviral therapy on Fetal subcutaneous fat tissue in HIV-pregnant women in a middle-income country","volume":"16","author":"Borboa-Olivares","year":"2023","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.bmc.2025.118338_bb0100","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1016\/S2352-3018(22)00327-7","article-title":"We should not stop considering HIV drug resistance testing at failure of first-line antiretroviral therapy","volume":"10","author":"Kantor","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.bmc.2025.118338_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/microorganisms11010221","article-title":"HIV and Drug-Resistant Subtypes","volume":"11","author":"Nastri","year":"2023","journal-title":"Microorganisms"},{"issue":"3","key":"10.1016\/j.bmc.2025.118338_bb0110","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1021\/acs.jmedchem.1c01885","article-title":"Development of novel Dihydrofuro[3,4-d]pyrimidine derivatives as HIV-1 NNRTIs to overcome the highly resistant mutant strains F227L\/V106A and K103N\/Y181C","volume":"65","author":"Kang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118338_bb0115","first-page":"12","article-title":"Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance","author":"Spielvogel","year":"2023","journal-title":"Elife"},{"issue":"7","key":"10.1016\/j.bmc.2025.118338_bb0120","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/hiv.12733","article-title":"Adverse effects of chronic treatment with the Main subclasses of highly active antiretroviral therapy: a systematic review","volume":"20","author":"Silva","year":"2019","journal-title":"HIV Med"},{"issue":"17","key":"10.1016\/j.bmc.2025.118338_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28176330","article-title":"Drug reprofiling to identify potential HIV-1 protease inhibitors","volume":"28","author":"Okafor","year":"2023","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.bmc.2025.118338_bb0130","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/jcb.30298","article-title":"Structure-based pharmacophore modeling, virtual screening approaches to identifying the potent hepatitis C viral protease and polymerase novel inhibitors","volume":"123","author":"Venkatesan","year":"2022","journal-title":"J Cell Biochem"},{"issue":"4","key":"10.1016\/j.bmc.2025.118338_bb0135","doi-asserted-by":"crossref","first-page":"E549","DOI":"10.1152\/ajpendo.2001.280.4.E549","article-title":"Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism","volume":"280","author":"Hruz","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.bmc.2025.118338_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129651","article-title":"Rational design, synthesis and biological evaluation of novel HIV-1 protease inhibitors containing 2-phenylacetamide derivatives as P2 ligands with potent activity against DRV-resistant HIV-1 variants","volume":"101","author":"Meng","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"issue":"22","key":"10.1016\/j.bmc.2025.118338_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214178","article-title":"Design and evaluation of novel HIV-1 protease inhibitors containing phenols or polyphenols as P2 ligands with high activity against DRV-resistant HIV-1 variants","volume":"23","author":"Ma","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118338_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113498","article-title":"Design and biological evaluation of cinnamic and phenylpropionic amide derivatives as novel dual inhibitors of HIV-1 protease and reverse transcriptase","volume":"220","author":"Zhu","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"14","key":"10.1016\/j.bmc.2025.118338_bb0155","doi-asserted-by":"crossref","first-page":"6328","DOI":"10.1021\/jm300238h","article-title":"Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance","volume":"55","author":"Parai","year":"2012","journal-title":"J Med Chem"},{"issue":"4945","key":"10.1016\/j.bmc.2025.118338_bb0160","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1126\/science.2106161","article-title":"Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer","volume":"247","author":"Matayoshi","year":"1990","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bmc.2025.118338_bb0165","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02425-17","article-title":"Mechanism of darunavir (DRV)\u2019s high genetic barrier to HIV-1 resistance: a key V32I substitution in protease rarely occurs, but once it occurs, it predisposes HIV-1 to develop DRV resistance","volume":"9","author":"Aoki","year":"2018","journal-title":"mBio"},{"issue":"8","key":"10.1016\/j.bmc.2025.118338_bb0170","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.bmcl.2011.02.105","article-title":"Pentacycloundecane-based inhibitors of wild-type C-south African HIV-protease","volume":"21","author":"Makatini","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"10.1016\/j.bmc.2025.118338_bb0175","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1128\/JCM.38.7.2688-2695.2000","article-title":"Evaluation of performance of the gen-probe human immunodeficiency virus type 1 viral load assay using primary subtype a, C, and D isolates from Kenya","volume":"38","author":"Emery","year":"2000","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.bmc.2025.118338_bb0180","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1080\/14756366.2019.1636234","article-title":"Kinetic and thermodynamic characterisation of HIV-protease inhibitors against E35D\u2191G\u2191S mutant in the south African HIV-1 subtype C protease","volume":"34","author":"Maseko","year":"2019","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"7","key":"10.1016\/j.bmc.2025.118338_bb0185","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s10930-013-9517-y","article-title":"F99 is critical for dimerization and activation of south African HIV-1 subtype C protease","volume":"32","author":"Naicker","year":"2013","journal-title":"Protein J"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625002792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625002792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:54:11Z","timestamp":1779771251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625002792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"alternative-id":["S0968089625002792"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118338","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design, synthesis, and evaluating primary biological activities of novel HIV-1 protease inhibitors containing heteraryl acetamides as the P2 ligands","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118338"}}